TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC lowered its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 29.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,471 shares of the biopharmaceutical company's stock after selling 53,849 shares during the period. Parkman Healthcare Partners LLC owned about 0.08% of TG Therapeutics worth $2,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. purchased a new stake in shares of TG Therapeutics during the 3rd quarter worth $759,000. Segall Bryant & Hamill LLC purchased a new stake in TG Therapeutics in the third quarter valued at $1,225,000. Principal Financial Group Inc. lifted its position in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at about $8,698,000. Finally, Marshall Wace LLP purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at about $36,501,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.50% of the company's stock.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.49 during mid-day trading on Wednesday, reaching $33.88. The company had a trading volume of 1,717,699 shares, compared to its average volume of 3,656,192. TG Therapeutics, Inc. has a 1 year low of $12.84 and a 1 year high of $36.84. The company has a market capitalization of $5.27 billion, a P/E ratio of -337.50 and a beta of 2.25. The stock's 50-day simple moving average is $27.03 and its 200-day simple moving average is $22.56. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period last year, the firm earned $0.73 EPS. The company's quarterly revenue was down 49.4% compared to the same quarter last year. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on TGTX. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. B. Riley upped their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective for the company. HC Wainwright upped their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.